Streetbeat News

Regulatory

NVDA

Nvidia's stock is experiencing a sell-off due to macroeconomic concerns and fears about its ability to maintain strong financial performance. Despite positive earnings and revenue growth, the stock has been affected by global market volatility, recession fears, and a DOJ subpoena rumor. Analysts still recommend buying the stock on weakness.

Portfolio Pulse from Shanthi Rexaline

September 05, 2024 | 1:01 pm

PW

Power REIT shares declined following a notice from NYSE regulation regarding non-compliance with listing standards.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:52 pm

EPI

FLIN

INDA

VIXY

VXX

BlackRock's Gargi Pal Chaudhuri advises investors to expect short-term volatility in U.S. equities but remain positive about medium- to long-term prospects, especially with potential Fed rate cuts. She also highlights India's market as a promising opportunity for foreign investors.

Portfolio Pulse from Surbhi Jain

September 05, 2024 | 12:47 pm

BAC

FTXO

KBWB

Bank of America is making a significant investment in carbon capture technology, investing $205 million in exchange for tax credits from Harvestone Low Carbon Partners. This move is part of a broader strategy to support climate technology and aligns with enhanced tax credits from the 2022 climate law. The investment highlights confidence in the Biden administration's climate policies.

Portfolio Pulse from Lekha Gupta

September 05, 2024 | 12:45 pm

BKTI

BK Technologies' BKR 9000 multiband radio has been approved by the National Interagency Fire Center for use by federal employees and contractors, qualifying it for purchase by the Department of the Interior for wildland fire operations.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:41 pm

BKTI

The National Interagency Fire Center has approved BK Technologies' BKR 9000 multiband radio, which is a significant development for the company.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:40 pm

INBS

Intelligent Bio Solutions is advancing towards completing its clinical study plan, a crucial step for FDA submission. This progress is significant for the company's future product approvals and market presence.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:36 pm

CTXR

Citius Pharmaceuticals' drug LYMPHIR has been added to the NCCN Clinical Practice Guidelines with a Category 2A recommendation for treating Cutaneous T-Cell Lymphoma.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:34 pm

SOPH

SOPHiA GENETICS, in collaboration with Boundless Bio and Precision for Medicine, has updated its clinical trial assay for oncogene amplified cancers. The partnership focuses on using SOPHiA's platform to identify patients with ecDNA amplified tumors, aiding Boundless Bio's cancer therapy development.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:34 pm

RVSN

Rail Vision has been granted a U.S. patent for its AI-powered railway obstacle detection system, which enhances safety and efficiency in railway operations.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:27 pm